Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Reta Peptide (Retatrutide): Triple Agonist Research Guide

Back to library
peptide

Reta Peptide (Retatrutide): Triple Agonist Research Guide

22 min read
Triple Agonist Research
GIP + GLP-1 + GCGR
Metabolic Research
Prescription-Only Research
Last Updated: May 2026

⚠ Prescription-only medication in many jurisdictions. For research purposes only. Not for human consumption.

Reta peptide (retatrutide) is the most advanced incretin-class compound currently in Phase 3 clinical development — a triple hormone receptor agonist that targets three distinct metabolic receptors simultaneously: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and, uniquely, the glucagon receptor (GCGR). That third target — the glucagon receptor — is what makes retatrutide mechanistically distinct from every previously studied GLP-1 class compound, and the central reason it has generated significant attention in the metabolic research community since the Phase 2 trial data was published in the New England Journal of Medicine in 2023.

This article provides a comprehensive mechanistic research guide to Reta peptide (retatrutide): what it is, how triple GIP/GLP-1/glucagon receptor agonism differs from dual and mono incretin approaches, what the published Phase 2 trial data documented, and how retatrutide compares to tirzepatide and semaglutide at the receptor level. All content is framed from a research chemistry and published literature perspective.

Retatrutide (LY3437943) is developed by Eli Lilly and Company and is currently in Phase 3 clinical development as of May 2026. It has not received regulatory approval in any jurisdiction. In the UK, retatrutide is not an approved medicine and falls outside the POM licensing framework on that basis — however, given the class of compound it belongs to and its pharmacological profile, it is supplied by Pure Grade Labs strictly as a research chemical for laboratory research purposes only. Not for human consumption or therapeutic use.

Key Takeaways

  • Triple receptor target: Retatrutide (the formal name for Reta peptide) simultaneously activates three receptors — GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). This triple agonism profile is unique among published incretin-class compounds and represents the defining mechanistic advance over tirzepatide’s dual GIP/GLP-1 agonism.
  • The glucagon receptor is the critical addition: Glucagon is a counter-regulatory hormone that drives hepatic glucose production and fatty acid oxidation. Adding GCGR agonism to the incretin backbone introduces a third mechanistic axis — hepatic metabolism — that GLP-1 and GIP receptor agonism alone cannot access. This is the central focus of retatrutide research.
  • Phase 2 trial data (Jastreboff et al. 2023, NEJM): The published retatrutide Phase 2 trial enrolled 338 participants across multiple dose arms over 48 weeks. It is the foundational clinical pharmacology dataset for Reta peptide and the primary source referenced in published incretin research on triple agonism.
  • Development stage: Retatrutide (LY3437943) is in Phase 3 clinical trials as of May 2026. It has not received approval from any regulatory body, including the FDA, EMA, or MHRA. It is not an approved medicine in the UK.
  • Research chemical supply: Pure Grade Labs supplies retatrutide 10mg as an HPLC-verified research chemical for laboratory research purposes only. This article does not constitute medical advice, and retatrutide is not intended for human consumption.
338
Participants in the Phase 2 retatrutide dose-finding trial (Jastreboff et al. 2023, NEJM)
48 wk
Duration of the Phase 2 retatrutide trial — the foundational published dataset for Reta peptide
3
Receptor targets: GIP-R, GLP-1R, and GCGR — making retatrutide the only published tri-agonist in its class
~5,442 Da
Approximate molecular weight of retatrutide (LY3437943) — 39 amino acids plus fatty acid moiety

Retatrutide (Reta Peptide) — UK Research Chemical Supply

Pure Grade Labs supplies retatrutide 10mg as an HPLC-verified research chemical with batch-specific COA. Available for qualified research procurement in the UK.

Prescription-only class compound. Supplied strictly as research chemical. Not for human consumption. Phase 3 clinical development — not approved in any jurisdiction.

View Retatrutide 10mg

What Is Reta Peptide? Retatrutide — Formal Chemical Identity

The compound colloquially referred to as Reta peptide is formally named retatrutide — an International Nonproprietary Name (INN) assigned to the molecule designated LY3437943 by its developer, Eli Lilly and Company. The “Reta” shorthand has emerged organically in research and online metabolic science communities as the colloquial reference to this compound, likely due to the convenience of a short identifier for a compound whose formal name (retatrutide) is less immediately memorable than prior incretin analogues such as semaglutide or tirzepatide.

Chemically, retatrutide is a 39-amino-acid synthetic peptide with a fatty acid moiety attached via a linker — structurally analogous in design philosophy to tirzepatide (LY3298176, also 39 amino acids with a C20 fatty diacid moiety). The approximate molecular weight of retatrutide is ~5,442 Da, reflecting the larger peptide backbone resulting from its triple-receptor engagement architecture compared to semaglutide’s 31-amino-acid, 4,113.6 Da structure. The fatty acid linker confers albumin-binding properties that extend the compound’s plasma half-life, enabling the weekly administration intervals used in its published clinical research.

The CAS registry number for retatrutide has not been widely published in the peer-reviewed literature as of May 2026, which is consistent with its investigational status. The compound is referenced in the scientific literature primarily by its INN (retatrutide) or Lilly development code (LY3437943). The foundational published characterisation is Coskun T et al. (2022, Diabetes, Obesity and Metabolism), which documented LY3437943’s receptor binding profile, pharmacokinetics, and in vitro activity at all three target receptors before Phase 2 data was available.

The Three-Receptor Model: GIP-R + GLP-1R + GCGR

To understand what makes Reta peptide (retatrutide) a fundamentally different research compound from any prior incretin-class molecule, it is necessary to understand what each of its three target receptors does and why adding the third — the glucagon receptor — creates a qualitatively distinct research context.

The GLP-1 Receptor (GLP-1R) — The Incretin Foundation

The GLP-1 receptor is a class B G-protein-coupled receptor (GPCR) expressed on pancreatic beta cells, hypothalamic satiety nuclei, brainstem vagal centres, and gastrointestinal enteroendocrine cells. When activated by GLP-1 or a GLP-1R agonist, the receptor couples to Gαs, stimulates adenylyl cyclase, elevates intracellular cAMP, and activates the PKA/EPAC signalling axis. In pancreatic beta cells, this produces glucose-dependent insulin secretion. In hypothalamic satiety circuits, GLP-1R activation drives neuronal signalling associated with satiety. In the gastrointestinal tract, it delays gastric emptying.

Semaglutide (Ozempic/Wegovy) acts exclusively through this receptor — a mono-agonist. It is the cleanest GLP-1R research tool compound available, and its published SUSTAIN and STEP trial programmes constitute the largest clinical dataset for selective GLP-1R agonism in human subjects. Retatrutide engages the same GLP-1R, but as one of three receptor targets rather than the sole pharmacological target.

The GIP Receptor (GIPR) — The Second Incretin Axis

The GIP receptor (GIPR) is also a class B1 GPCR, activated by the incretin hormone glucose-dependent insulinotropic polypeptide (GIP). Like GLP-1R, it stimulates glucose-dependent insulin secretion from pancreatic beta cells via cAMP/PKA signalling. However, GIPR has a significantly different tissue distribution that creates distinct research dimensions beyond pancreatic function: GIPR is expressed on adipocytes (where it has documented roles in lipid metabolism and fatty acid uptake), osteoblasts and osteoclasts (bone turnover), and hypothalamic neurons. Tirzepatide’s dual GIP/GLP-1 receptor agonism was the first clinical programme to systematically exploit GIPR co-activation — and the mechanistic paradox of GIP (which promotes adipose lipid storage endogenously but appears to produce different outcomes in dual agonism context) remains an active research question.

Retatrutide also engages GIPR, contributing this incretin axis to its pharmacological profile alongside GLP-1R. The net effect of dual GIP + GLP-1 receptor engagement in retatrutide is therefore structurally similar to tirzepatide’s receptor targeting — but retatrutide adds a third, entirely separate receptor class that neither tirzepatide nor semaglutide engages.

The Glucagon Receptor (GCGR) — The Critical Third Target

Glucagon is a 29-amino-acid peptide hormone secreted by pancreatic alpha cells in response to hypoglycaemia, fasting, and metabolic stress. Its primary physiological role is counter-regulatory: glucagon raises blood glucose by stimulating hepatic glycogenolysis (breakdown of stored glycogen) and gluconeogenesis (synthesis of glucose from non-glucose precursors). The glucagon receptor (GCGR) is a class B1 GPCR expressed primarily on hepatocytes, with additional expression in kidney, adipose tissue, and the heart.

From a metabolic research perspective, glucagon receptor activation has two properties that are directly relevant to why Eli Lilly’s research team chose to incorporate GCGR agonism into the triple agonist design:

  • Hepatic energy expenditure: Glucagon drives hepatic fatty acid oxidation — the breakdown of stored lipids in liver cells. This is a distinct mechanism from GLP-1R-mediated gastric emptying delay and GIP-mediated adipose signalling. GCGR agonism in hepatocytes activates cAMP/PKA signalling that upregulates fatty acid beta-oxidation pathways and mitochondrial biogenesis markers. In research models, this has been investigated as a mechanism for addressing hepatic steatosis (fat accumulation in the liver) — a condition that GLP-1 mono-agonism alone has limited direct mechanistic effect on at the hepatic level.
  • Increased energy expenditure: Glucagon increases basal metabolic rate, an effect documented through thyroid hormone pathway cross-talk and direct thermogenic effects. In preclinical models, GCGR agonism elevates oxygen consumption and energy expenditure — a mechanistic property not present in pure incretin agonists.

The research design rationale for adding GCGR to GIP + GLP-1 receptor agonism is that the three receptors, when co-activated, engage three complementary metabolic axes simultaneously: GLP-1R drives satiety signalling and insulin secretion; GIPR adds pancreatic co-stimulation and adipose tissue GIPR signalling; GCGR drives hepatic energy mobilisation and metabolic rate elevation. The mechanistic hypothesis is that these three axes, engaged simultaneously by a single molecule, produce additive or synergistic metabolic research effects that no dual or mono agonist can replicate.

The Glucagon Receptor in Metabolic Research: Why It Changes the Research Context

The glucagon receptor’s inclusion in retatrutide’s receptor target profile is not an incremental addition — it is a categorical shift in the mechanistic scope of what an incretin-class compound can study. To understand why, it is worth examining what had historically prevented pure glucagon receptor agonism from being developed as a standalone research compound.

Glucagon itself, when administered as a mono-agonist, raises blood glucose via glycogenolysis and gluconeogenesis — a useful emergency hyperglycaemia correction mechanism but an obvious liability when the research context involves the metabolic complications of glucose dysregulation. Standalone GCGR agonism would be expected to worsen glucose parameters, making it unsuitable as a mono-agonist research compound in metabolic models.

The mechanistic insight that made triple agonism viable is that co-activation of GLP-1R and GCGR simultaneously neutralises the hyperglycaemic risk of glucagon receptor activation: the GLP-1R component drives glucose-dependent insulin secretion, providing a glucose-lowering counterbalance to GCGR-mediated hepatic glucose output. This “yin-yang” pairing — one receptor raising glucose output, one suppressing it — was the theoretical foundation that led researchers to investigate GLP-1R + GCGR dual agonism as early as 2009 (Day JW et al., Nature Chemical Biology 2009, published the first unimolecular GLP-1/glucagon dual agonist concept).

What retatrutide adds to this framework is the GIPR component — a third receptor that contributes complementary pancreatic beta cell co-stimulation and adipose tissue signalling, potentially amplifying the overall metabolic research signal beyond what GLP-1R + GCGR dual agonism alone produces. This tri-agonist architecture — where each receptor’s pharmacological liability is counterbalanced by another receptor’s activity — is the scientific rationale published in Coskun T et al. (2022) for the LY3437943 molecular design.

The Phase 2 Retatrutide Trial: Jastreboff et al. 2023 (NEJM)

The Phase 2 retatrutide clinical trial was published in the New England Journal of Medicine in June 2023 (Jastreboff AM et al., “Triple hormone receptor agonist retatrutide for obesity,” N Engl J Med 2023;389:514–526). This is the foundational published dataset for Reta peptide in human subjects and the primary source of clinical pharmacology data used by researchers investigating retatrutide’s in vivo receptor engagement profile.

Trial Design and Participant Population

The trial was a randomised, double-blind, placebo-controlled, dose-ranging Phase 2 study. It enrolled 338 participants with a body mass index of 27 kg/m² or higher (without type 2 diabetes) at 40 sites in the United States. The trial ran for 48 weeks of treatment followed by a 28-week follow-up period. This design — a dose-ranging study — was intended to characterise the dose-response relationship across multiple retatrutide dose levels before Phase 3 development.

Dose Arms

Participants were randomised across six treatment arms: placebo and five active dose arms of retatrutide at 1 mg, 4 mg, 8 mg, 12 mg, and 12 mg (with a different uptitration schedule). This multi-arm dose-ranging design provided a detailed characterisation of the pharmacodynamic response across a broad retatrutide dose range — a standard Phase 2 design for investigational peptide compounds intended to inform Phase 3 dose selection.

Published Findings — Research Context

The published NEJM paper reported dose-dependent changes across multiple measured endpoints. The findings documented in the paper are cited here strictly as historical research data — as records of what was measured in a controlled clinical experimental setting under defined conditions — not as treatment predictions or therapeutic recommendations:

  • All active dose arms produced statistically significant differences in body weight compared to placebo at 48 weeks. The dose-response relationship was clearly documented across the five active arms.
  • The 12 mg dose arms produced the largest magnitude body weight changes in the trial — reported as the primary efficacy endpoint in the published paper. The specific percentage values are documented in the NEJM publication and cited in subsequent reviews of the Phase 2 dataset.
  • The trial measured multiple secondary endpoints including waist circumference, cardiometabolic markers, and safety parameters. The full endpoint dataset is documented in the published supplementary data available through the NEJM.
  • The Phase 2 safety data documented that retatrutide’s adverse event profile was consistent with other incretin-class compounds — gastrointestinal events (nausea, vomiting, diarrhoea) were the most common treatment-emergent adverse events and were dose-dependent in frequency.
  • Notably, despite the GCGR component of retatrutide’s pharmacology, the trial documented no clinically significant hyperglycaemia — confirming the theoretical prediction that GLP-1R co-activation counterbalances the glycaemia-elevating effect of GCGR agonism in the context of triple agonism.

The Jastreboff et al. 2023 paper is the most cited published source for retatrutide Phase 2 data and is available in full through the NEJM archive. Researchers studying triple agonism pharmacology should treat this paper — along with Coskun et al. 2022 — as the foundational scientific references for any Reta peptide research design.

Phase 3 Development Status (May 2026)

Following the Phase 2 results, Eli Lilly advanced retatrutide into Phase 3 clinical development. As of May 2026, Phase 3 trials are underway. Retatrutide has not received regulatory approval from any agency — including the FDA, EMA, or MHRA in the UK. There is no approved clinical indication for retatrutide in any jurisdiction. It remains an investigational compound. This Phase 3 development context is important for researchers: the compound’s pharmacological profile is well-characterised at Phase 2 level, but the complete Phase 3 dataset has not yet been published.

Triple Receptor Architecture: Retatrutide vs Tirzepatide vs Semaglutide

The table below provides a mechanistic comparison of the three principal incretin-class research compounds available from Pure Grade Labs, structured by receptor target, development stage, and published trial programme. This comparison is intended to assist researchers in identifying which compound is appropriate for their specific receptor pharmacology research question.

Parameter Semaglutide
(Ozempic/Wegovy)
Tirzepatide
(Mounjaro)
Retatrutide
(Reta Peptide / LY3437943)
Receptor targets GLP-1R only GIPR + GLP-1R GIPR + GLP-1R + GCGR
Agonist class Mono-agonist (GLP-1R selective) Dual agonist (twincretin) Triple agonist (tri-agonist)
Glucagon receptor (GCGR) No engagement No engagement Full GCGR agonism — hepatic energy mobilisation, fatty acid oxidation pathway activation
Peptide backbone GLP-1 based, 31 AA GIP based, 39 AA Novel sequence, 39 AA
Molecular weight 4,113.6 Da ~4,813 Da ~5,442 Da
Developer Novo Nordisk Eli Lilly (LY3298176) Eli Lilly (LY3437943)
Regulatory status (UK) Approved POM (HMR 2012) Approved POM (HMR 2012) Not approved — investigational (Phase 3 trials ongoing as of May 2026)
Key published trial SUSTAIN-6 (3,297 participants, NEJM 2016); STEP 1 (1,961 participants, NEJM 2021) SURPASS-2 (1,879 participants, NEJM 2021); SURMOUNT-1 (2,539 participants, NEJM 2022) Phase 2 (338 participants, 48 weeks, NEJM 2023 — Jastreboff AM et al.)
Research supply (Pure Grade Labs) Semaglutide 10mg Tirzepatide 10mg Retatrutide 10mg

Complete Incretin Research Compound Range

Pure Grade Labs supplies semaglutide, tirzepatide, and retatrutide as HPLC-verified research chemicals with batch-specific COA. The Metabolic Research Stack bundles these compounds for comparative incretin receptor research.

All three compounds are prescription-only class molecules. Supplied strictly as research chemicals for laboratory purposes. Not for human consumption.

How Retatrutide Compares to Tirzepatide: The Glucagon Receptor Addition

For researchers already familiar with tirzepatide, the mechanistic question about retatrutide is specific: what does adding the glucagon receptor actually change about the research context? This is the most important mechanistic distinction to understand when evaluating Reta peptide as a research tool.

Tirzepatide engages two receptor pathways: GLP-1R and GIPR. Both are incretin receptors — both are expressed on pancreatic beta cells, both produce glucose-dependent insulin secretion via cAMP/PKA signalling, and both engage peripheral and central metabolic circuits. Their downstream signalling is complementary but mechanistically related — they are both class B1 GPCRs responding to post-prandial nutrient signals, evolved for similar physiological purposes.

The glucagon receptor (GCGR) is categorically different. It is also a class B1 GPCR, but it is activated by glucagon — a counter-regulatory hormone whose physiological function is the opposite of incretin action. Where GLP-1 and GIP signal “nutrients present — store and utilise,” glucagon signals “energy deficit — mobilise hepatic stores.” GCGR agonism therefore introduces a mechanistically distinct hepatic pathway that the incretin receptors alone cannot activate:

  • Hepatic fatty acid oxidation: GCGR activation in hepatocytes stimulates fatty acid beta-oxidation via the cAMP/PKA axis — increasing the rate at which hepatocytes break down stored lipids for energy. This is the primary mechanism hypothesised to contribute to retatrutide’s distinctive hepatic research profile, and it is a mechanism absent from both semaglutide and tirzepatide’s pharmacological repertoire.
  • Basal metabolic rate: Glucagon has documented thermogenic effects — GCGR activation increases oxygen consumption and metabolic rate via sympathetic nervous system pathway interaction. In preclinical models, GCGR agonism elevates energy expenditure independently of food intake — a mechanistic addition that pure incretin agonists do not provide.
  • Hepatic glucose output: The hyperglycaemic potential of GCGR agonism — its stimulation of hepatic glycogenolysis and gluconeogenesis — is counterbalanced in retatrutide by the GLP-1R-mediated insulin secretion component. The NEJM Phase 2 paper confirmed this counterbalancing effect in practice: no clinically significant hyperglycaemia was observed despite the GCGR agonism component.

For researchers whose investigation specifically concerns hepatic lipid metabolism, fatty acid oxidation pathways, or the contribution of basal metabolic rate elevation to metabolic research models, retatrutide provides a mechanistic dimension that tirzepatide cannot. Conversely, for researchers whose question is specifically about GIPR/GLP-1R dual agonism in isolation — without the hepatic GCGR confound — tirzepatide remains the cleaner research tool.

How Retatrutide Compares to Semaglutide: Three Axes vs One

The comparison between Reta peptide (retatrutide) and semaglutide is the most mechanistically straightforward of the three pairings. Semaglutide activates GLP-1R only. Retatrutide activates GLP-1R, GIPR, and GCGR. Every pharmacological effect that semaglutide produces via GLP-1R agonism is also present — in some form — in retatrutide’s pharmacological profile. But retatrutide adds two entire additional receptor axes on top.

For researchers using semaglutide as a GLP-1R-only control in a comparative study, retatrutide — or tirzepatide — would be the natural active compound for studying what the additional receptor targets contribute. The semaglutide/retatrutide mechanistic comparison is particularly informative for researchers whose question is: what is the contribution of GIPR + GCGR co-activation (beyond GLP-1R baseline) to the overall metabolic research signal?

The published clinical data comparison — STEP 1 (semaglutide 2.4mg, 1,961 participants, 68 weeks) versus the Phase 2 retatrutide data (338 participants, 48 weeks) — is not directly head-to-head (different trial populations, durations, and study designs). Researchers should consult the primary publications for each compound independently rather than drawing direct cross-trial comparisons from the published data alone.

Research-Grade Specifications: Retatrutide

For laboratory researchers sourcing retatrutide as a research chemical, the following specifications are relevant to research design and compound handling:

  • Formal name: Retatrutide (INN) / LY3437943 (Lilly development code)
  • Colloquial name: Reta peptide (used in research community shorthand)
  • Peptide length: 39 amino acids
  • Approximate molecular weight: ~5,442 Da
  • Structural features: Novel amino acid sequence (not GLP-1 or GIP backbone) + fatty acid moiety via linker for albumin binding and extended half-life
  • Receptor targets: GIPR, GLP-1R, GCGR (class B1 GPCRs)
  • Development stage: Phase 3 clinical trials (as of May 2026) — not approved in any jurisdiction
  • Pure Grade Labs supply: 10mg vials, HPLC-verified, batch-specific COA available — Retatrutide 10mg research chemical
  • Storage: Lyophilised powder — store at −20°C, protect from light and moisture; reconstituted solution should be kept at 4°C and used promptly per standard peptide research handling protocols
Research Context
The question Lilly’s research team was trying to answer was not “what if we add another receptor to tirzepatide?” It was more fundamental: why does glucagon — a hormone associated with energy deficit and hepatic glucose mobilisation — seem to produce beneficial effects on liver fat in animal models of metabolic liver disease, when the obvious prediction would be the opposite?

The mechanistic thread begins with the observation that in obese rodent models with hepatic steatosis, GCGR agonism consistently reduced hepatic fat content — not by reducing food intake (a GLP-1R mechanism) but by directly upregulating fatty acid oxidation pathways in hepatocytes. The liver, expressing high levels of GCGR, responds to glucagon receptor activation by increasing mitochondrial beta-oxidation and lipolysis of intrahepatic lipid stores. This is mechanistically distinct from anything a GLP-1 or GIP receptor agonist can accomplish directly at the hepatic level.

The problem was hyperglycaemia: standalone GCGR agonism raises blood glucose, making it unsuitable in isolation. The resolution — co-activating GLP-1R to drive glucose-dependent insulin secretion simultaneously — transformed GCGR agonism from a liability into an asset. Add GIPR for complementary pancreatic co-stimulation, and you have retatrutide: a molecule where each receptor’s pharmacological contribution is specifically selected to either add a desired research-relevant mechanism or counterbalance another receptor’s potential liability.

The 338-participant Phase 2 trial published in the NEJM in 2023 was the first systematic clinical documentation of what that three-receptor strategy produces in human subjects across multiple dose levels over 48 weeks. It is the primary evidence base from which all current retatrutide research hypotheses are drawn.

Frequently Asked Questions: Reta Peptide (Retatrutide)

What is Reta peptide (retatrutide)?

Reta peptide is the colloquial name for retatrutide — a synthetic 39-amino-acid tri-agonist peptide developed by Eli Lilly and Company under the internal designation LY3437943. It simultaneously activates three receptors: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple receptor engagement profile is unique among all published incretin-class compounds. Retatrutide is currently in Phase 3 clinical trials (as of May 2026) and has not received regulatory approval in any jurisdiction. Pure Grade Labs supplies retatrutide 10mg strictly as a research chemical for laboratory research purposes — not for human consumption or therapeutic use.

How does retatrutide differ from tirzepatide (Mounjaro)?

Both retatrutide and tirzepatide are Eli Lilly compounds with similar 39-amino-acid peptide architectures and fatty acid albumin-binding moieties. Tirzepatide is a dual agonist — it activates GIPR and GLP-1R only. Retatrutide is a triple agonist — it activates GIPR, GLP-1R, and additionally the glucagon receptor (GCGR). The glucagon receptor is the defining mechanistic addition: GCGR agonism activates hepatic fatty acid oxidation pathways and increases basal metabolic rate via mechanisms that pure incretin agonism (GIP + GLP-1) cannot access. For researchers whose question involves hepatic lipid metabolism or the glucagon receptor pathway specifically, retatrutide is the appropriate compound. For researchers studying dual incretin agonism in isolation, tirzepatide remains the cleaner mechanistic tool.

What does the glucagon receptor do in metabolic research?

The glucagon receptor (GCGR) is a class B1 GPCR expressed primarily on hepatocytes. Its endogenous ligand, glucagon, is a counter-regulatory hormone that raises blood glucose via hepatic glycogenolysis and gluconeogenesis during fasting and hypoglycaemia. In research contexts, GCGR agonism is studied for two properties distinct from incretin receptor biology: (1) stimulation of hepatic fatty acid oxidation — GCGR activation via cAMP/PKA upregulates beta-oxidation of intrahepatic lipids, a mechanism relevant to research on hepatic steatosis and liver lipid metabolism; and (2) basal metabolic rate elevation — glucagon has documented thermogenic effects via sympathetic nervous system pathway interaction. In retatrutide’s triple agonist design, the potential hyperglycaemic effect of GCGR activation is counterbalanced by the GLP-1R component’s glucose-dependent insulin secretion — a counterbalancing strategy confirmed by the absence of clinically significant hyperglycaemia in the Phase 2 trial (Jastreboff et al. 2023).

What did the Phase 2 retatrutide trial find?

The Phase 2 retatrutide trial (Jastreboff AM et al., N Engl J Med 2023;389:514–526) enrolled 338 participants without type 2 diabetes across 40 US sites in a randomised, double-blind, placebo-controlled, dose-ranging design over 48 weeks. Five active dose arms (1mg, 4mg, 8mg, 12mg, and 12mg with a different uptitration schedule) were compared to placebo. All active dose arms produced statistically significant body weight changes versus placebo at 48 weeks, with a clear dose-response relationship. The 12mg dose arms produced the largest effects — documented in full in the published NEJM paper and available through the journal archive. The safety profile was consistent with incretin-class compounds (primarily gastrointestinal adverse events). No clinically significant hyperglycaemia was documented, confirming the predicted GLP-1R/GCGR counterbalancing mechanism. This Phase 2 dataset is the foundational published evidence for Reta peptide’s clinical pharmacology.

Is retatrutide available in the UK?

Retatrutide is not an approved medicine in the UK. It has not received approval from the MHRA, FDA, EMA, or any regulatory body as of May 2026, and remains an investigational compound in Phase 3 clinical development. It is therefore not available through the pharmaceutical prescription pathway in the UK. Pure Grade Labs supplies retatrutide 10mg as a research chemical under the research-use framework — for laboratory research, in vitro experimentation, and preclinical scientific purposes only, not for human consumption. Researchers sourcing retatrutide in this context should ensure their use complies with all applicable institutional and jurisdictional regulations and that the compound is handled solely for legitimate laboratory research purposes.

Source Retatrutide and Incretin Research Compounds from Pure Grade Labs

Retatrutide (Reta peptide), tirzepatide, and semaglutide available as HPLC-verified research chemicals — 99%+ purity, batch-specific COA with every order. UK supply.

All compounds are prescription-only class molecules. Supplied strictly as research chemicals for laboratory purposes. Not for human consumption or therapeutic use.

Summary: Reta Peptide (Retatrutide) as a Triple Agonist Research Tool

Reta peptide — formally retatrutide (LY3437943) — represents the current frontier of incretin-class receptor pharmacology research. Where semaglutide (GLP-1R only) and tirzepatide (GIPR + GLP-1R) progressively expanded the number of receptors engaged, retatrutide adds a third, categorically distinct receptor — the glucagon receptor (GCGR) — that introduces hepatic fatty acid oxidation and basal metabolic rate elevation as mechanistic axes absent from all prior incretin-class compounds.

The mechanistic design rationale is clear in the published literature: GLP-1R counterbalances GCGR’s hyperglycaemic potential while itself contributing satiety signalling and glucose-dependent insulin secretion; GIPR adds pancreatic beta cell co-stimulation and adipose tissue GIPR signalling; GCGR provides the hepatic lipid metabolism and thermogenic dimension that makes triple agonism a qualitatively distinct research proposition from dual incretin approaches. The Phase 2 NEJM paper (Jastreboff et al. 2023, 338 participants, 48 weeks) confirmed that this three-receptor architecture produces dose-dependent metabolic research signals in human subjects across all five active dose arms — without the hyperglycaemia that would be expected from isolated GCGR agonism.

For metabolic research laboratories investigating incretin receptor pharmacology, comparative receptor agonism, hepatic lipid metabolism, or the mechanistic basis of tri-agonist signalling, retatrutide is the only published compound that enables three-receptor co-activation in a single stable peptide molecule. It is in Phase 3 clinical development as of May 2026, with no regulatory approval in any jurisdiction — and is available from Pure Grade Labs as an HPLC-verified research chemical for laboratory research purposes only.


References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
  2. Coskun T, Sloop KW, Loghin C, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycaemic control and body composition research. Diabetes, Obesity and Metabolism. 2022;24(6):1126–1140. doi:10.1111/dom.14628
  3. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the metabolic effects of GLP-1? Trends in Endocrinology & Metabolism. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006 [Functionally selective GIP receptor agonism context]
  4. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010 [GLP-1 receptor background reference]
  5. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology. 2009;5(10):749–757. doi:10.1038/nchembio.209 [Foundational GLP-1/glucagon dual agonism concept]
  6. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
  7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
Prescription-Only Class Compound & Research Use Disclaimer: Retatrutide (Reta peptide / LY3437943) is an investigational compound in Phase 3 clinical development as of May 2026. It has not received regulatory approval from any authority including the MHRA (UK), FDA (USA), or EMA (EU). It is not an approved medicine in any jurisdiction. Pure Grade Labs supplies retatrutide strictly as a research chemical for laboratory research purposes only. It is not intended for human consumption, self-administration, or any therapeutic use. This article does not constitute medical advice. All clinical trial data cited (Jastreboff et al. 2023 Phase 2 NEJM) is referenced as historical published scientific record for mechanistic research context only — it does not constitute a therapeutic recommendation, efficacy claim, or endorsement of any specific use. Nothing in this article should be construed as positioning retatrutide as a weight-loss solution or as guidance for any human use outcome. Researchers must comply with all applicable regulations in their jurisdiction. Pure Grade Labs is a UK research chemical supplier operating under a research-use framework.